[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388799":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":155,"collaborators":20,"id":157,"slug":158,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":159,"sex":165,"minAge":166,"maxAge":20,"enrollmentInfo":167,"targetDuration":20,"studyType":170,"phases":171,"briefSummary":173,"conditions":174,"keywords":20,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Toxicity test","EXPERIMENTAL","For all patients, the NovaGray RILA Breast® test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection) and in the case of adjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection).\n\nThe test consists of a blood sample of 2x4 mL",[13],"Device: NovaGray RILA Breast® test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","NovaGray RILA Breast® test","The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Marian Gutowski","STUDY_CHAIR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Aurore MOUSSION","CONTACT","04 67 61 31 02","+33","DRCI-icm105@icm.unicancer.fr",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":31},"Emmanuelle TEXIER",[35,52,65,78,91,103,116,129,142],{"facility":36,"status":37,"city":38,"state":20,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Centre Georges François Leclerc","RECRUITING","Dijon","21079","France","FR",{"type":43,"coordinates":44},"Point",[45,46],5.01391,47.31344,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":20,"phoneExt":20,"email":51},"Laura VINCENT","lvincent@cgfl.fr",{"facility":53,"status":37,"city":54,"state":20,"zip":55,"country":40,"countryCode":41,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Centre Oscar Lambret","Lille","59000",{"type":43,"coordinates":57},[58,59],3.05512,50.63391,{"lat":59,"lon":58},[62],{"name":63,"role":28,"phone":20,"phoneExt":20,"email":64},"Marie Pierre Chauvet","mp-chauvet@o-lambret.fr",{"facility":66,"status":37,"city":67,"state":20,"zip":68,"country":40,"countryCode":41,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Centre Léon Bérard","Lyon","69373",{"type":43,"coordinates":70},[71,72],4.84789,45.74906,{"lat":72,"lon":71},[75],{"name":76,"role":28,"phone":20,"phoneExt":20,"email":77},"Marie-Adele Dammacco","marie-adele.dammacco@lyon.unicancer.fr",{"facility":79,"status":37,"city":80,"state":20,"zip":81,"country":40,"countryCode":41,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Institut Paoli Calmette","Marseille","13009",{"type":43,"coordinates":83},[84,85],5.38107,43.29695,{"lat":85,"lon":84},[88],{"name":89,"role":28,"phone":20,"phoneExt":20,"email":90},"Marie Bannier","bannierm@ipc.unicancer.fr",{"facility":92,"status":37,"city":93,"state":20,"zip":94,"country":40,"countryCode":41,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Institut du Cancer de Montpellier","Montpellier","34298",{"type":43,"coordinates":96},[97,98],3.87635,43.61093,{"lat":98,"lon":97},[101],{"name":23,"role":28,"phone":20,"phoneExt":20,"email":102},"marian.gutowski@icm.unicancer.fr",{"facility":104,"status":37,"city":105,"state":20,"zip":106,"country":40,"countryCode":41,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"centre Antoine Lacassagne","Nice","06189",{"type":43,"coordinates":108},[109,110],7.26608,43.70313,{"lat":110,"lon":109},[113],{"name":114,"role":28,"phone":20,"phoneExt":20,"email":115},"Maud DUQUESNE","maud.duquesne@nice.unicancer.fr",{"facility":117,"status":37,"city":118,"state":20,"zip":119,"country":40,"countryCode":41,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Hôpital Tenon","Paris","75970",{"type":43,"coordinates":121},[122,123],2.3488,48.85341,{"lat":123,"lon":122},[126],{"name":127,"role":28,"phone":20,"phoneExt":20,"email":128},"Michael Atlan","michael.atlan@aphp.fr",{"facility":130,"status":37,"city":131,"state":20,"zip":132,"country":40,"countryCode":41,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Institut de Cancérologie de l'Ouest","Saint-Herblain","44805",{"type":43,"coordinates":134},[135,136],-1.651,47.21154,{"lat":136,"lon":135},[139],{"name":140,"role":28,"phone":20,"phoneExt":20,"email":141},"Victoire Brillaud-Meflah","victoire.brillaud-meflah@ico.unicancer.fr",{"facility":143,"status":37,"city":144,"state":20,"zip":145,"country":40,"countryCode":41,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Institut Claudius Regaud","Toulouse","31059",{"type":43,"coordinates":147},[148,149],1.44367,43.60426,{"lat":149,"lon":148},[152],{"name":153,"role":28,"phone":20,"phoneExt":20,"email":154},"Carole MASSABEAU","massabeau.carole@iuct-oncopole.fr",{"type":156,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100388799","predictive-toxicity-test-linked-to-radiotherapy-after-mastectomy-and-immediate-implant-reconstruction-100388799",false,"NCT04342546","Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction","Prospective Evaluation of a Predictive Toxicity Test Post Radiotherapy After Mastectomy With Immediate Implant Reconstruction","PRETORIA","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed\n* Indication of wall chest radiation after mastectomy\n* Patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center)\n* Performance Status 0-1\n* Consent signed before any study procedure\n* Patient geographically accessible for follow-up\n* Affiliated to the French national social security system\n\nExclusion Criteria:\n\n* Breast reconstruction with flap\n* Inflammatory breast cancer (cT4d)\n* Skin or parietal breast cancer (cT4 a, b or c)\n* Metastatic patients\n* Patients with bilateral breast cancer\n* History of homolateral breast cancer treated with radiotherapy\n* History of contralateral breast cancer\n* Pregnant or breastfeeding women\n* Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent\n* Participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy","MALE","18 Years",{"count":168,"type":169},250,"ESTIMATED","INTERVENTIONAL",[172],"NA","This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.",[175,176],"Breast Cancer","Capsular Contracture Associated With Breast Implant","2026-04-08",{"date":179,"type":180},"2026-04-13","ACTUAL",{"date":182,"type":180},"2020-12-11",{"date":184,"type":169},"2031-12-10",{"name":5,"class":6},9]